Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial
作者： G. S. Chatta , T. M. Feinstein , L. J. Appleman , D. M. Friedland , S. A. Jacobs
DOI: 10.1200/JCO.2008.26.15_SUPPL.5148
关键词:
摘要: 5148 Background: Docetaxel has a survival benefit in CRPC. Oral and IV platinum derivatives have activity We hypothesized that novel combination of docetaxel oxaliplatin may be benef...
sci-hub.st 参考文章(0)